Magazine Article | April 5, 2010

Monoclonal Antibodies: The Next Generation

Source: Life Science Leader

By Cliff Mintz Ph.D., Life Science Leader magazine.

The commercial success of therapeutic monoclonal antibodies (MAbs) to treat cancer, immune dysfunction, and infectious diseases has catapulted these once difficult-to-develop molecules to the forefront of modern molecular medicine. While MAbs are rapidly becoming commonplace in today’s therapeutic treatment armamentarium, it wasn’t until the mid to late 1990s that their full therapeutic and commercial potential were realized.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online

Please tell us more about you so that we can customize our newsletters to your specific interests: